tailieunhanh - MammaPrint guides treatment decisions in breast Cancer: Results of the IMPACt tria

Increased usage of genomic risk assessment assays suggests increased reliance on data provided by these assays to guide therapy decisions. The current study aimed to assess the change in treatment decision and physician confidence based on the 70-gene risk of recurrence signature (70-GS, MammaPrint) and the 80-gene molecular subtype signature (80-GS, BluePrint) in early stage breast cancer patients. | MammaPrint guides treatment decisions in breast Cancer Results of the IMPACt tria

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN